LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials
SAN DIEGO — Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe's ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.
Article content
The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival. 3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3 -ITD identifies AML patients in remission who are most likely to relapse or experience poor survival. 3,4,5 With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.
Article content
'We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,' said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. 'This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we're further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.'
Article content
LabPMM's NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat ® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM's full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
Article content
About Invivoscribe
Article content
Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
Article content
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
The biggest piece of Mars on Earth is going up for auction in New York
A Martian meteorite, weighing 54.388 lbs. (24.67 kg), said to be the largest piece of Mars on Earth, estimated at $2 - 4 million, is displayed at Sotheby's, in New York, Wednesday, July 9, 2025, part of their Geek Week auction, July 16, 2025. (AP Photo/Richard Drew) NEW YORK — For sale: A 54-pound (25-kilogram) rock. Estimated auction price: US$2 million to $4 million. Why so expensive? It's the largest piece of Mars ever found on Earth. Sotheby's in New York will be auctioning what's known as NWA 16788 on Wednesday as part of a natural history-themed sale that also includes a juvenile Ceratosaurus dinosaur skeleton that's more than six feet (two metres) tall and nearly 11 feet (three metres) long. According to the auction house, the meteorite is believed to have been blown off the surface of Mars by a massive asteroid strike before traveling 140 million miles (225 million kilometres) to Earth, where it crashed into the Sahara. A meteorite hunter found it in Niger in November 2023, Sotheby's says. The red, brown and gray hunk is about 70 per cent larger than the next largest piece of Mars found on Earth and represents nearly seven per cent of all the Martian material currently on this planet, Sotheby's says. It measures nearly 15 inches by 11 inches by six inches (375 millimetres by 279 millimetres by 152 millimetres). 'This Martian meteorite is the largest piece of Mars we have ever found by a long shot,' Cassandra Hatton, vice chairman for science and natural history at Sotheby's, said in an interview. 'So it's more than double the size of what we previously thought was the largest piece of Mars.' It is also a rare find. There are only 400 Martian meteorites out of the more than 77,000 officially recognized meteorites found on Earth, Sotheby's says. Hatton said a small piece of the red planet remnant was removed and sent to a specialized lab that confirmed it is from Mars. It was compared with the distinct chemical composition of Martian meteorites discovered during the Viking space probe that landed on Mars in 1976, she said. The examination found that it is an 'olivine-microgabbroic shergottite,' a type of Martian rock formed from the slow cooling of Martian magma. It has a course-grained texture and contains the minerals pyroxene and olivine, Sotheby's says. It also has a glassy surface, likely due to the high heat that burned it when it fell through Earth's atmosphere, Hatton said. 'So that was their first clue that this wasn't just some big rock on the ground,' she said. The meteorite previously was on exhibit at the Italian Space Agency in Rome. Sotheby's did not disclose the owner. It's not clear exactly when the meteorite hit Earth, but testing shows it probably happened in recent years, Sotheby's said. The juvenile Ceratosaurus nasicornis skeleton was found in 1996 near Laramie, Wyoming, at Bone Cabin Quarry, a gold mine for dinosaur bones. Specialists assembled nearly 140 fossil bones with some sculpted materials to recreate the skeleton and mounted it so it's ready to exhibit, Sotheby's says. The skeleton is believed to be from the late Jurassic period, about 150 million years ago, Sotheby's says. It's auction estimate is $4 million to $6 million. Ceratosaurus dinosaurs were bipeds with short arms that appear similar to the Tyrannosaurus rex, but smaller. Ceratosaurus dinosaurs could grow up to 25 feet (7.6 metres) long, while the Tyrannosaurs rex could be 40 feet (12 metres) long. The skeleton was acquired last year by Fossilogic, a Utah-based fossil preparation and mounting company. Wednesday's auction is part of Sotheby's Geek Week 2025 and features 122 items, including other meteorites, fossils and gem-quality minerals. Collins reported from Hartford, Connecticut. Dave Collins And Joseph B. Frederick, The Associated Press
Toronto Sun
15 hours ago
- Toronto Sun
Charges dropped against Utah doctor accused of throwing away $28K in COVID vaccine doses
Published Jul 12, 2025 • 2 minute read Attorney General Pam Bondi speaks to the media, Friday, June 27, 2025, in the briefing room of the White House in Washington. Photo by Jacquelyn Martin / AP The federal government on Saturday dismissed charges against a Utah plastic surgeon accused of throwing away COVID-19 vaccines, giving children saline shots instead of the vaccine and selling faked vaccination cards. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account U.S. Attorney General Pam Bondi said in a post on the social media platform X that charges against Dr. Michael Kirk Moore, of Midvale, Utah, were dismissed at her direction. Moore and other defendants faced up to 35 years in prison after being charged with conspiracy to defraud the government; conspiracy to convert, sell, convey and dispose of government property; and aiding and abetting in those efforts. The charges were brought when Joe Biden was president. 'Dr. Moore gave his patients a choice when the federal government refused to do so,' Bondi wrote. 'He did not deserve the years in prison he was facing. It ends today.' Felice John Viti, acting U.S. attorney for Utah, filed the motion Saturday, saying 'such dismissal is in the interests of justice.' Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. The trial began Monday in Salt Lake City with jury selection. It was expected to last 15 days. Messages sent to the U.S. Department of Justice, Viti's office in Salt Lake City and to Moore were not immediately returned Saturday to The Associated Press. A federal grand jury on Jan. 11, 2023, returned an indictment against Moore, his Plastic Surgery Institute of Utah Inc., others associated with the clinic and a neighbor of Moore's. The indictment alleged more than $28,000 of government-provided COVID-19 vaccine doses were destroyed. They were also accused of providing fraudulently completed vaccination record cards for over 1,900 doses of the vaccine in exchange for either a cash or a donation to a specified charitable organization. This advertisement has not loaded yet, but your article continues below. The government also alleged some children were given saline shots, at their parents' request, so the minors believed they were getting the vaccine. Health Secretary Robert Kennedy Jr., a leading anti-vaccine activist before becoming the nation's top health official, posted his support for Moore in April, saying on X that Moore 'deserves a medal for his courage and his commitment to healing!' During his confirmation hearings in January, Kennedy repeatedly refused to acknowledge scientific consensus that childhood vaccines don't cause autism and that COVID-19 vaccines saved millions of lives. In a follow-up X post on Saturday, Bondi said Georgia Republican Rep. Marjorie Taylor Greene brought the case to her attention. World Toronto Raptors Relationships Columnists MLB
Globe and Mail
20 hours ago
- Globe and Mail
UnitedHealth: Down 50%, Is the Dividend Still Safe?
UnitedHealth Group (NYSE: UNH) faces a series of unprecedented challenges, from leadership crises to federal investigations, leading to a significant stock decline. Is this the end of its dominance? *Stock prices used were the market prices of July 8, 2025. The video was published on July 12, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Rick Orford has positions in UnitedHealth Group. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
